Experimental HCV Drugs
Experimental HCV Drugs
AIDS 2012: Adding Nitazoxanide Does Not Improve Interferon Cure Rate for HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 24 August 2012 00:00
- Written by Liz Highleyman
Addition of the anti-protozoal drug Nitazoxanide (Alinia) to pegylated interferon plus ribavirin for treatment of chronic hepatitis C did not lead to higher likelihood of sustained virological response (SVR) in a study of people with HIV, but it may confer an advantage for people with unfavorable IL28B gene patterns, according to a study presented last month at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.
Early Biomarker Changes Predict Which Hepatitis C Patients Develop Severe Liver Disease
- Details
- Category: HCV Treatment
- Published on Friday, 10 August 2012 00:00
- Written by Press Release
People with chronic hepatitis C who have persistently elevated levels of alanine aminotransferase (ALT) and the pro-fibrogenic chemokine monocyte chemotactic protein-1 (MCP-1, also known as CCL-2) during the early stages of infection are significantly more likely to develop advanced liver fibrosis or cirrhosis, according to a small study reported in the July 24, 2012, Proceedings of the National Academy of Sciences. 
Advocates Release Updated Report on Pipeline Drugs for HIV, Hepatitis C, and TB
- Details
- Category: Experimental HIV Drugs
- Published on Saturday, 21 July 2012 00:00
- Written by Press Release
Drugs are HIV are more effective and plentiful than ever, but in many cases they are not making it into the hands of people who need them, according the 2012 Pipeline Report, released July 21 by HIV i-Base and the Treatment Action Group (TAG). Development of new direct-acting agents for hepatitis C, however, is occurring at a rapid pace.
Hepatitis C Polymerase Inhibitor BMS-986094 Suspended Due to Safety Concern
- Details
- Category: HCV Treatment
- Published on Tuesday, 07 August 2012 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) last week announced that it is halting development of its experimental hepatitis C virus (HCV) nucleotide polymerase inhibitor BMS-986094 to protect patient safety after identification of "serious safety issue" during a Phase 2 study.
New Study Will Test Simeprevir plus Daclatasvir for Previously Untreated Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 06 July 2012 00:00
- Written by Press Release
Researchers will soon begin testing an interferon-free dual oral regimen of simeprevir (better known as TMC435) plus daclatasvir (formerly BMS-790052) for treatment-naive genotype 1 chronic hepatitis C patients, co-developer Medivir announced last week.
Web Design and Development by